236 related articles for article (PubMed ID: 31835809)
41. Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy.
Gan JJ; Garcia V; Tian J; Tagliati M; Parisi JE; Chung JM; Lewis R; Baloh R; Levade T; Pierson TM
Neuromuscul Disord; 2015 Dec; 25(12):959-63. PubMed ID: 26526000
[TBL] [Abstract][Full Text] [Related]
42. Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.
Yu FPS; Dworski S; Medin JA
Sci Rep; 2018 Jan; 8(1):1808. PubMed ID: 29379059
[TBL] [Abstract][Full Text] [Related]
43. Targeting acid sphingomyelinase reduces cardiac ceramide accumulation in the post-ischemic heart.
Klevstig M; Ståhlman M; Lundqvist A; Scharin Täng M; Fogelstrand P; Adiels M; Andersson L; Kolesnick R; Jeppsson A; Borén J; Levin MC
J Mol Cell Cardiol; 2016 Apr; 93():69-72. PubMed ID: 26930027
[TBL] [Abstract][Full Text] [Related]
44. Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls.
Momoi T; Ben-Yoseph Y; Nadler HL
Biochem J; 1982 Aug; 205(2):419-25. PubMed ID: 6814427
[TBL] [Abstract][Full Text] [Related]
45. Spinal muscular atrophy associated with progressive myoclonus epilepsy.
Topaloglu H; Melki J
Epileptic Disord; 2016 Sep; 18(S2):128-134. PubMed ID: 27647482
[TBL] [Abstract][Full Text] [Related]
46. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications.
Kornhuber J; Tripal P; Reichel M; Mühle C; Rhein C; Muehlbacher M; Groemer TW; Gulbins E
Cell Physiol Biochem; 2010; 26(1):9-20. PubMed ID: 20502000
[TBL] [Abstract][Full Text] [Related]
47. Acid sphingomyelinase promotes SGK1-dependent vascular calcification.
Luong TTD; Tuffaha R; Schuchardt M; Moser B; Schelski N; Boehme B; Gollmann-Tepeköylü C; Schramm C; Holfeld J; Pieske B; Gulbins E; Tölle M; van der Giet M; Lang F; Eckardt KU; Voelkl J; Alesutan I
Clin Sci (Lond); 2021 Feb; 135(3):515-534. PubMed ID: 33479769
[TBL] [Abstract][Full Text] [Related]
48. Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner.
Bayerle A; Marsching C; Rabionet M; Dworski S; Kamani MA; Chitraju C; Gluchowski NL; Gabriel KR; Herzer S; Jennemann R; Levade T; Medin JA; Sandhoff R
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158741. PubMed ID: 32474112
[TBL] [Abstract][Full Text] [Related]
49. Molecular analysis of acid ceramidase deficiency in patients with Farber disease.
Bär J; Linke T; Ferlinz K; Neumann U; Schuchman EH; Sandhoff K
Hum Mutat; 2001 Mar; 17(3):199-209. PubMed ID: 11241842
[TBL] [Abstract][Full Text] [Related]
50. Development of an acid ceramidase activity-based probe.
Ouairy CM; Ferraz MJ; Boot RG; Baggelaar MP; van der Stelt M; Appelman M; van der Marel GA; Florea BI; Aerts JM; Overkleeft HS
Chem Commun (Camb); 2015 Apr; 51(28):6161-3. PubMed ID: 25748248
[TBL] [Abstract][Full Text] [Related]
51. The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease.
Levade T; Tempesta MC; Salvayre R
FEBS Lett; 1993 Aug; 329(3):306-12. PubMed ID: 8365472
[TBL] [Abstract][Full Text] [Related]
52. Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis.
Bodas M; Pehote G; Silverberg D; Gulbins E; Vij N
Free Radic Biol Med; 2019 Feb; 131():81-97. PubMed ID: 30500419
[TBL] [Abstract][Full Text] [Related]
53. Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase.
He X; Okino N; Dhami R; Dagan A; Gatt S; Schulze H; Sandhoff K; Schuchman EH
J Biol Chem; 2003 Aug; 278(35):32978-86. PubMed ID: 12815059
[TBL] [Abstract][Full Text] [Related]
54. C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease.
Cozma C; Iurașcu MI; Eichler S; Hovakimyan M; Brandau O; Zielke S; Böttcher T; Giese AK; Lukas J; Rolfs A
Sci Rep; 2017 Jul; 7(1):6149. PubMed ID: 28733637
[TBL] [Abstract][Full Text] [Related]
55. Ceramide mediates lung fibrosis in cystic fibrosis.
Ziobro R; Henry B; Edwards MJ; Lentsch AB; Gulbins E
Biochem Biophys Res Commun; 2013 May; 434(4):705-9. PubMed ID: 23523785
[TBL] [Abstract][Full Text] [Related]
56. In situ assay of acid sphingomyelinase and ceramidase based on LDL-mediated lysosomal targeting of ceramide-labeled sphingomyelin.
Levade T; Leruth M; Graber D; Moisand A; Vermeersch S; Salvayre R; Courtoy PJ
J Lipid Res; 1996 Dec; 37(12):2525-38. PubMed ID: 9017505
[TBL] [Abstract][Full Text] [Related]
57. Farber lipogranulomatosis type 1--late presentation and early death in a Croatian boy with a novel homozygous ASAH1 mutation.
Cvitanovic-Sojat L; Gjergja Juraski R; Sabourdy F; Fensom AH; Fumic K; Paschke E; Levade T
Eur J Paediatr Neurol; 2011 Mar; 15(2):171-3. PubMed ID: 20609603
[TBL] [Abstract][Full Text] [Related]
58. Acid and neutral sphingomyelinase, ceramide synthase, and acid ceramidase activities in cutaneous aging.
Jensen JM; Förl M; Winoto-Morbach S; Seite S; Schunck M; Proksch E; Schütze S
Exp Dermatol; 2005 Aug; 14(8):609-18. PubMed ID: 16026583
[TBL] [Abstract][Full Text] [Related]
59. Regulation of Neuronal Stem Cell Proliferation in the Hippocampus by Endothelial Ceramide.
Gulbins A; Grassmé H; Hoehn R; Wilker B; Soddemann M; Kohnen M; Edwards MJ; Kornhuber J; Gulbins E
Cell Physiol Biochem; 2016; 39(2):790-801. PubMed ID: 27475812
[TBL] [Abstract][Full Text] [Related]
60. Liposome-targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation.
Aldosari MH; de Vries RP; Rodriguez LR; Hesen NA; Beztsinna N; van Kuilenburg ABP; Hollak CEM; Schellekens H; Mastrobattista E
Eur J Pharm Biopharm; 2019 Apr; 137():185-195. PubMed ID: 30818011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
